Research Snappy
  • Market Research Forum
  • Investment Research
  • Consumer Research
  • More
    • Advertising Research
    • Healthcare Research
    • Data Analysis
    • Top Companies
    • Latest News
No Result
View All Result
Research Snappy
No Result
View All Result

Eric Aguiar Sells 3,537 Shares of Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Stock

researchsnappy by researchsnappy
December 19, 2019
in Healthcare Research
0
Eric Aguiar Sells 3,537 Shares of Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Stock
399
SHARES
2.3k
VIEWS
Share on FacebookShare on Twitter

Biohaven Pharmaceutical logoBiohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) Director Eric Aguiar sold 3,537 shares of the stock in a transaction on Monday, December 16th. The shares were sold at an average price of $55.13, for a total value of $194,994.81. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Eric Aguiar also recently made the following trade(s):

  • On Monday, December 9th, Eric Aguiar sold 4,072 shares of Biohaven Pharmaceutical stock. The shares were sold at an average price of $55.11, for a total value of $224,407.92.
  • On Wednesday, November 20th, Eric Aguiar sold 6,729 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $52.20, for a total value of $351,253.80.
  • On Friday, November 22nd, Eric Aguiar sold 1,250 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $55.24, for a total value of $69,050.00.

Shares of NYSE BHVN traded down $0.99 during midday trading on Wednesday, reaching $52.13. The company had a trading volume of 580,883 shares, compared to its average volume of 712,597. Biohaven Pharmaceutical Holding Co Ltd has a one year low of $29.17 and a one year high of $67.86. The firm’s fifty day moving average price is $51.94 and its 200-day moving average price is $46.53. The stock has a market cap of $2.74 billion, a PE ratio of -8.48 and a beta of 0.46.

Biohaven Pharmaceutical (NYSE:BHVN) last posted its quarterly earnings results on Friday, November 1st. The company reported ($2.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.57) by ($0.47). As a group, research analysts anticipate that Biohaven Pharmaceutical Holding Co Ltd will post -7.55 earnings per share for the current fiscal year.

Several equities analysts have recently commented on BHVN shares. ValuEngine upgraded Biohaven Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Saturday, December 7th. Zacks Investment Research downgraded Biohaven Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Monday, October 21st. William Blair reaffirmed a “buy” rating on shares of Biohaven Pharmaceutical in a research note on Tuesday, December 10th. Canaccord Genuity set a $80.00 price target on shares of Biohaven Pharmaceutical and gave the company a “buy” rating in a research report on Monday, August 26th. Finally, Goldman Sachs Group set a $89.00 price target on shares of Biohaven Pharmaceutical and gave the stock a “buy” rating in a research note on Wednesday, September 4th. Four analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Biohaven Pharmaceutical currently has a consensus rating of “Buy” and a consensus target price of $71.42.

Hedge funds have recently made changes to their positions in the business. Nisa Investment Advisors LLC boosted its stake in shares of Biohaven Pharmaceutical by 511.1% during the third quarter. Nisa Investment Advisors LLC now owns 1,100 shares of the company’s stock valued at $46,000 after purchasing an additional 920 shares during the period. Tower Research Capital LLC TRC purchased a new position in shares of Biohaven Pharmaceutical in the second quarter worth $65,000. Aperio Group LLC purchased a new position in shares of Biohaven Pharmaceutical in the second quarter worth $71,000. Glen Harbor Capital Management LLC raised its holdings in Biohaven Pharmaceutical by 165.9% during the 2nd quarter. Glen Harbor Capital Management LLC now owns 1,744 shares of the company’s stock valued at $76,000 after buying an additional 1,088 shares during the last quarter. Finally, Canton Hathaway LLC bought a new stake in Biohaven Pharmaceutical during the 3rd quarter valued at $83,000. Hedge funds and other institutional investors own 92.83% of the company’s stock.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.

Recommended Story: Liquidity

Insider Buying and Selling by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)



Receive News & Ratings for Biohaven Pharmaceutical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com’s FREE daily email newsletter.

Previous Post

Relationship between ethanol consumption and TBL2 rs17145738 on LDL-C concentration in Japanese adults: a four season 3-day weighed diet record study | BMC Nutrition

Next Post

Enrollment Services Raises Funds for EOA Children’s House

Next Post
Enrollment Services Raises Funds for EOA Children’s House

Enrollment Services Raises Funds for EOA Children's House

Research Snappy

Category

  • Advertising Research
  • Consumer Research
  • Data Analysis
  • Healthcare Research
  • Investment Research
  • News
  • Top Company News

Top 10 Market Research Companies in the world

Market Research 101: How to Make Data Your Superpower

The Role of Artificial Intelligence in Transforming Market Research

  • Privacy Policy
  • Terms of Use
  • Antispam
  • DMCA
  • Contact Us

© 2023 researchsnappy.com

No Result
View All Result
  • Market Research Forum
  • Investment Research
  • Consumer Research
  • More
    • Advertising Research
    • Healthcare Research
    • Data Analysis
    • Top Companies
    • Latest News

© 2023 researchsnappy.com